ASX Quarterly Health Wrap: Imricor starts CY25 strong, Clever Culture eyes FY25 profit
ASX quarterly season is upon us again, with listed companies opening a window to their performance and key activities over the three months to March 31.
It's a key time for investors to zero in on the finer details of ASX-listed firms and get a sense of what is on the horizon.
Here, we wrap up report highlights from four standout stocks in the ASX health sector.
Imricor Medical Systems (ASX:IMR)
Imricor submitted second module for premarket approval of its products to US FDA during quarter
Second -generation Vision-MR Ablation Catheter receives CE mark certification under new European Medical Device Regulation
After quarter end Imricor started its VISABL-VT pivotal trial at Amsterdam University Medical Centre achieving world-firsts
Imricor, which has developed the world's only MRI-compatible devices for cardiac ablations, made several regulatory achievements during Q1 CY25 including submitting the second module for premarket approval of its products to the US Food and Drug Administration (FDA).
Among other highlights of a milestone quarter for the company, IMR received CE Mark approval for its second generation Vision-MR Ablation Catheter under the new more stringent European Medical Device Regulation (MDR).
Subsequent to quarter end, Imricor started its VISABL-VT pivotal trial at Amsterdam University Medical Centre, achieving the first-in-human ventricular ablation guided by real-time iCMR.
On the commercial front, the company is rebuilding its European sales team with the first capital sales managers in the US hired in preparation for commercial launch.
Imricor B.V. was established in the Netherlands with the company opening an office in Amsterdam. The company also attended the Gulf Arrhythmia Congress in Dubai and EHRA Congress in Vienna.
Imricor finished Q1 FY25 with a strong cash position following a $70 million capital raising, closing with a cash balance of US$53.9m (~A$85.5m).
Race Oncology (ASX:RAC)
Race made significant progress in Q3 FY25 towards first patient treatment in its phase I trial of its cardioprotective therapeutic RC220 in combination with doxorubicin in patients with advanced solid tumours.
Ethics and all regulatory approvals were received for the lead site of Southside Cancer Care Centre, in Miranda NSW enabling recruitment of patients.
Screening of patients has begun and the treatment of the first patient with RC220 is expected in the current quarter.
Human ethics approval was also received to begin the trial at the Gosford and Wyong Hospitals, in the Central Coast Local Health District of NSW.
Race said ethics approval allowed both the Gosford and Wyong Hospitals to enrol patients subject to final site approvals and activation. Final approvals are expected during April.
As of March 31, 2025, Race held cash and cash equivalents of $17.12m. The company said more than 70% of spending during Q3 ($1.67m) was directed toward R&D and drug manufacturing activities.
"Like everyone at Race, I am looking forward to seeing the first patient treated with RC220 in this quarter and converting RC220's potential into meaningful outcomes for cancer patients and our shareholders," CEO Dr Daniel Tillett said.
Clever Culture CEO and managing director Brent Barnes said just over 12 months since its launched its APAS (automated plate assessment system) Independence instruments (culture plate readers) in the pharmaceutical market, the response had been "overwhelmingly positive" as it targets FY25 profitability.
The company has 13 instruments sold or pre-ordered to date, representing ~$6m in revenue. That will set a base for future recurring revenue from licence fees and maintenance support.
In a trading update, Clever Culture said it was building a substantial sales pipeline to underpin FY26 growth with 40 active and qualified customer opportunities within the pharmaceutical industry, representing ~$75m in potential upfront sales revenue and $15m per annum recurring revenue.
The company's APAS Independence instruments remain the only US FDA-cleared AI technology for automated culture plate reading.
A second purchase order has been received from an additional Bristol Myers Squibb (BMS) facility, which is expected to form a case study for the potential roll out to other BMS sites.
Another big-pharma was completing an expanded 6000 plate evaluation, clearing the way for procurement discussions direct with their manufacturing sites.
The company said active engagement with potential customers had accelerated noticeably since it announced the planned launch of a second APAS analysis module for analysis of the smaller contact plates (55mm) in October 2024.
Combined with the existing APAS analysis module for the settle plates (90mm), the APAS Independence will be able to analyse the two plate types that make up the vast majority of tests used by pharmaceutical manufacturers in environmental monitoring.
"Our strategy has been to target global pharmaceutical manufacturers that operate multiple sites globally and represent multi-instrument sales opportunities," Barnes said.
Over the past three months the APAS Independence Instruments had been showcased at several leading international conferences.
Genomic life sciences company EZZ successfully launched two new products during Q3 FY25, which it said leveraged consumer insights to meet evolving market trends and enhance the company's competitive positioning.
EZZ also upgraded the formulas and packaging of three of its top selling products and strengthened domestic distribution by securing listings in ~70 new retail pharmacy distribution points in Australia.
The company also progressed its strategic entry into the US market through comprehensive market research, collaboration with key local partners, and the development of a phased market entry plan targeted for H2 FY25.
One of the highlights of Q3 was EZZ's elevated brand awareness, with the company serving an ace in its inaugural sponsorship of the Australian Open in January covering China and Southeast Asia, including influencer-hosted livestreams and content creation.
EZZ said the campaign, it biggest marketing venture to date, delivered strong visibility across China and Southeast Asia, supported by prominent on-court branding.
Meanwhile, the company continued to strengthen its brand positioning and consumer engagement on leading e-commerce platforms and initiated new customer loyalty initiatives to drive long-term growth in China.
The company also reinforced industry presence and global networking through participation in the Cosmoprof Worldwide Bologna and the Australian Pharmacy Professional (APP) Conference nd Trade Exhibition, both held in March.
Receipts from customers totalled $14.6m during Q3, which EZZ said reflected lower seasonal turnover in January and February compared to PCP, partly due to reduced digital advertising spend.
The company said strong operating performance resulted in $1.5m of positive cash inflow. Cash reserves reached a record $21.1 million as at March 31 2025, with EZZ remaining debt-free, excluding lease liabilities.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

AU Financial Review
an hour ago
- AU Financial Review
Cinema giant flags part-sale of Sydney's George Street complex
Some of the real estate behind one of Sydney's most popular cinema complexes, Event Cinemas on George Street, is up for sale with its ASX-listed owner EVT keen to channel the proceeds into its hotels division instead. At a corporate level, the listing of 525 George Street – one of the buildings that make up the overall complex – is part of EVT's 'asset maximisation programme'.


Perth Now
an hour ago
- Perth Now
500 jobs axed in major Jetstar move
Qantas has announced it will close Jetstar Asia, its Singapore-based budget airline after two decades in the air, as it looks to focus on the domestic market. In an announcement to the ASX Qantas said the closure of Jetstar Asia will enable the airline to recycle up to $500m in capital and support its fleet renewal program. The airline said it would redirect 13 Jetstar Asia Airbus A320 aircraft to be progressively redeployed to Australia and New Zealand, adding 100 local jobs in the process. The decision will have zero impact to all of Jetstar and Jetstar Japan's flying into Asia. None of the highly popular routes they operate into Indonesia, Vietnam, Japan, Singapore are affected. The restructure could see up to 500 jobs axed from its Singapore operation. A statement to the ASX said employees of Jetstar Asia would be provided with redundancy benefits and employment support services, and Qantas was working to find job opportunities elsewhere in the group or with other airlines in the region. Qantas announces it is axing its Jetstar Asia flights. NewsWire / Luis Enrique Ascui Credit: News Corp Australia The airline said the closure would have a cost of approximately $175m due to one-off redundancy and restructuring costs with the first third coming this financial year, with the rest coming in 2026. Qantas Group CEO Vanessa Hudson said Jetstar Asia has been a pioneering force in the Asian aviation market for more than 20 years, making air travel accessible to millions of customers across Southeast Asia. 'We are incredibly proud of the Jetstar Asia team and the work they have done to deliver low fares, strong operational performance and exceptional customer service. This is a very tough day for them. Despite their best efforts, we have seen some of Jetstar Asia's supplier costs increase by up to 200 per cent, which has materially changed its cost base.' Qantas chief executive Vanessa Hudson thanked the Jetstar Asia crew. Qantas/NewsWire Credit: Supplied 'I want to sincerely thank and acknowledge our incredible Jetstar Asia team who should be very proud of the impact they have had on aviation in the region over the past two decades.' Qantas said the closure came after a deterioration in Jetstar Asia's earnings, with the airline facing strong competition from AirAsia and Singapore's own national carrier. Qantas said it expected the subsidiary to post an underlying earnings loss of $25 million in the six months to June 30.


West Australian
2 hours ago
- West Australian
St George kicks off drill assault on mammoth Brazil niobium play
St George Mining has launched a major drilling assault at its giant Araxá rare earths project in Minas Gerais, Brazil, with the company deploying three drill rigs for a substantial 10,000-metre program over the next three or so months. St George's sizable undertaking follows a recently unveiled globally significant maiden resource at Araxá, comprising 40.64 million tonnes (Mt) at 4.13 per cent total rare earth oxides (TREO) and 41.2Mt at 0.68 per cent niobium pentoxide. The campaign will be carried out alongside a high-resolution airborne magnetic survey, which is set to kick off next week. The 10,000m drilling program aims to significantly expand this resource base by combining auger, reverse circulation and diamond drilling to target the Araxá mineralisation, which remains open in all directions. The company says untested high-grade zones below 100m depth were not included in the resource. Historical drilling intersected more than 500 high-grade intercepts, including standout results such as a massive 60m at 11.1 per cent TREO, a substantial 43m grading 1.5 per cent niobium and a higher-grade 20m running 2.4 per cent niobium. Impressively, all these hits started at surface. The company's imminent drone-based airborne magnetic survey will cover the entire project area to define the carbonatite-hosted deposit's geological model and pinpoint the extent of its niobium and rare earths targets. Araxá's standout features include its free-dig near-surface resource, which sits almost entirely within 100m depth and is ideal for low-cost open-pit mining. Located in Brazil's mining-friendly Minas Gerais state, the project sits adjacent to CBMM's world-class niobium mine, which has a massive 896Mt at 1.49 per cent niobium. St George's robust local infrastructure and access to a skilled workforce enabled it to secure government backing for expedited approvals and assemble a top-tier in-country team including several former CBMM executives. The project also stacks up well against global peers such as Lynas Rare Earths' Mt Weld mine, with its massive 106Mt at 4.1 per cent TREO, and MP Materials' Mountain Pass, which holds 40.6Mt at 5.9 per cent TREO. Araxá's 40.64Mt at 4.13 per cent TREO translates to a whopping 1.7Mt of contained TREO, including 320,000 tonnes of high-value neodymium and praseodymium and 280,000t niobium, which could be just the beginning. With auger drilling already underway, the company is hoping the latest drilling results will further uncover what looks to be the next world-class mine to emerge from the fabled Brazilian carbonatite complex. Is your ASX-listed company doing something interesting? Contact: